Protagonist Therapeutics, Inc Marketable Securities (Current)
Protagonist Therapeutics, Inc (PTGX) had Marketable Securities (Current) of $362.50 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:MarketableSecuritiesCurrent · last filed 2026-08-05
- 2026-06-30: Marketable Securities, Current $362.50M.
- 2026-03-31: Marketable Securities, Current $354.07M.
- 2025-12-31: Marketable Securities, Current $438.97M.
- 2025-09-30: Marketable Securities, Current $462.40M.
| Period end | Marketable Securities, Current |
|---|---|
| 2026-06-30 | $362.50M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $354.07M 10-Q · filed 2026-05-05 |
| 2025-12-31 | $438.97M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $462.40M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $401.92M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $434.71M 10-Q · filed 2025-05-06 |
| 2024-12-31 | $321.66M 10-K · filed 2026-02-25 |
| 2024-09-30 | $337.60M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $208.35M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $150.07M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $154.89M 10-K · filed 2025-02-21 |
| 2023-09-30 | $90.22M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $78.02M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $103.07M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $111.61M 10-K · filed 2024-02-27 |
| 2022-09-30 | $114.62M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $171.65M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $206.81M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $203.24M 10-K · filed 2023-03-15 |
| 2021-09-30 | $193.76M 10-Q · filed 2021-11-03 |
| 2021-06-30 | $161.87M 10-Q · filed 2021-08-04 |
| 2021-03-31 | $190.48M 10-Q · filed 2021-05-04 |
| 2020-12-31 | $188.45M 10-K · filed 2022-02-28 |
| 2020-09-30 | $110.35M 10-Q · filed 2020-11-04 |
| 2020-06-30 | $62.42M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $57.30M 10-Q · filed 2020-05-07 |
| 2019-12-31 | $100.01M 10-K · filed 2021-03-10 |
| 2019-09-30 | $87.50M 10-Q · filed 2019-11-06 |
| 2019-06-30 | $54.96M 10-Q · filed 2019-08-07 |
| 2018-12-31 | $46.62M 10-K · filed 2020-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |